- Report
- March 2024
- 124 Pages
From €1450EUR$1,500USD£1,246GBP
- Report
- April 2018
- 100 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Report
- January 2018
- 120 Pages
Global
From €579EUR$599USD£497GBP
- Report
- March 2022
- 172 Pages
Global
From €5963EUR$6,168USD£5,122GBP
- Report
- March 2022
- 180 Pages
Global
From €5577EUR$5,769USD£4,791GBP
- Book
- February 2023
- 672 Pages
- Book
- September 2022
- 480 Pages
- Book
- July 2022
- 880 Pages
- Book
- October 2020
- 800 Pages
- Book
- December 2019
- 432 Pages
- Book
- December 2019
- 432 Pages
- Book
- March 2015
- 512 Pages
Myocardial infarction (MI) is a type of cardiovascular disease that occurs when the blood supply to the heart is blocked, leading to the death of heart muscle tissue. It is the most common type of heart attack and is a major cause of death and disability worldwide. Treatment for MI typically involves medications, lifestyle changes, and in some cases, surgery.
The MI market within the context of cardiology is a rapidly growing sector, driven by the increasing prevalence of cardiovascular diseases and the need for better treatments. The market is expected to benefit from the development of new technologies and treatments, such as stem cell therapy and gene therapy. Additionally, the increasing demand for minimally invasive procedures is expected to drive the market growth.
Some of the key players in the MI market include Abbott Laboratories, Boston Scientific Corporation, Medtronic, Johnson & Johnson, St. Jude Medical, and Biotronik. Show Less Read more